Get the Stockscreener App
27.71
0.27%
-0.09
After Hours:
27.70
-0.01
-0.04%
Roivant Sciences Ltd stock is traded at $27.71, with a volume of 4.65M.
It is down -0.27% in the last 24 hours and up +2.12% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$27.80
Open:
$27.71
24h Volume:
4.65M
Relative Volume:
0.70
Market Cap:
$19.82B
Revenue:
$13.31M
Net Income/Loss:
$-1.01B
P/E Ratio:
-23.71
EPS:
-1.1685
Net Cash Flow:
$-766.86M
1W Performance:
-1.19%
1M Performance:
+2.12%
6M Performance:
+84.34%
1Y Performance:
+152.73%
1-Day Range:
$27.12
$27.96
1-Week Range:
$27.12
$28.95
52-Week Range:
$8.73
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
27.69 | 19.90B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
454.18 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.79 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.62 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ONC
Beone Medicines Ltd Adr
|
274.97 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Bernstein initiates Roivant Sciences stock with outperform rating - Investing.com
Sanford C. Bernstein Begins Coverage on Roivant Sciences (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Insider Sold Shares Worth $5,648,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares - MarketBeat
Roivant (NASDAQ: ROIV) president exercises 200K options and sells 200K shares - Stock Titan
Trade Recap: What is the dividend yield of Roivant Sciences LtdShort Setup & AI Based Trade Execution Alerts - baoquankhu1.vn
Roivant Sciences Insider Sold Shares Worth $1,200,573, According to a Recent SEC Filing - marketscreener.com
Insider Sell Alert: Melissa Epperly Sells 41,861 Shares of Roiva - GuruFocus
Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 41,861 Shares - MarketBeat
Roivant Sciences (ROIV) director sells 41,861 common shares - Stock Titan
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Aug Catalysts: Can Roivant Sciences Ltd outperform under higher oil prices2026 PreEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rockefeller Financial files to sell 200,000 Roivant shares | ROIV SEC FilingForm 144 - Stock Titan
Aug Reactions: Is Roivant Sciences Ltd stock undervalued right nowWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd. - National Today
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY - MarketBeat
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - MSN
Roivant Sciences Ltd. $ROIV Shares Purchased by HighVista Strategies LLC - MarketBeat
Roivant Sciences Ltd. $ROIV is Foursixthree Capital LP's 7th Largest Position - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Sold by Prosight Management LP - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Bought by Integral Health Asset Management LLC - MarketBeat
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent LitigationSlideshow (NASDAQ:ROIV) 2026-03-13 - Seeking Alpha
Roivant Sciences stock hits all-time high at 30.31 USD - Investing.com Nigeria
Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72% - Markets Mojo
Roivant Sciences stock hits all-time high at 30.31 USD By Investing.com - Investing.com Canada
Leerink Partners maintains Roivant Sciences (ROIV) outperform recommendation - MSN
Roivant at Leerink Conference: Strategic Transformation Insights - Investing.com Australia
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
(ROIV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Nigeria
WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright - The Globe and Mail
Aug Rallies: Can Roivant Sciences Ltd. sustain earnings growthQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Dow Update: Can Roivant Sciences Ltd outperform under higher oil pricesJuly 2025 Intraday Action & Weekly High Return Forecasts - baoquankhu1.vn
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Blue Owl Capital Holdings LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) reports Q3 loss, misses revenue estimates - MSN
Sentiment Review: Is Roivant Sciences Ltd stock undervalued right nowGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds By Investing.com - Investing.com South Africa
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Mar 17 '26 |
Sale |
28.24 |
200,000 |
5,648,000 |
1,647,546 |
| Epperly Melissa B, | Director |
Mar 16 '26 |
Sale |
28.68 |
41,861 |
1,200,573 |
15,804 |
0.44%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):